Vanda Pharmaceuticals, Inc.’s new drug application (NDA) for tradipitant for the treatment of symptoms in gastroparesis was rejected by the US Food and Drug Administration, but the company still intends to file tradipitant in a different indication – motion sickness – by the end of the year.
Vanda’s Tradipitant Gets CRL In Gastroparesis But Another NDA Filing Is Still On
The company will file a new drug application with the US FDA by the end of the year for tradipitant in a different indication, motion sickness.
